Clinical commissioning policy: Lomitapide for treating homozygous familial hypercholesterolaemia (adults)

Document first published:
Page updated:
Topic:
,
Publication type:

Lomitapide is recommended to be available as a routine commissioning treatment option for homozygous familial hypercholesterolaemia within the criteria set out in this document.

Document

Clinical Commissioning Policy: Lomitapide for treating homozygous familial hypercholesterolaemia (adults)

Clinical Commissioning Policy: Lomitapide for treating homozygous familial hypercholesterolaemia (adults)

  • PDF
  • 293 KB
  • 9 pages

Summary

Published 26 March 2025.

Document

Clinical panel report: Lomitapide (urn1679) for familial homozygous hypercholesterolaemia

Clinical panel report: Lomitapide (urn1679) for familial homozygous hypercholesterolaemia

  • PDF
  • 233 KB
  • 3 pages

Summary

Clinical evidence evaluation criteria for a proposition for a clinical commissioning policy for routine commissioning: Lomitapide (urn1679) for familial homozygous hypercholesterolaemia.

Published 26 March 2025.

Document

Clinical evidence review: Lomitapide (urn1679) for familial homozygous hypercholesterolaemia

Clinical evidence review: Lomitapide (urn1679) for familial homozygous hypercholesterolaemia

  • PDF
  • 703 KB
  • 74 pages

Summary

Clinical evidence review of lomitapide for treating homozygous familial hypercholesterolaemia in adults.

Published 26 March 2025.